Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get
Business

Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get

April 6, 2026
Benzinga
Scroll

Apellis jumps as Biogen agrees 5.6 Billion acquisition, offering 41/share plus milestones, boosting rare-disease portfolio. Importance Rank: 1 read more

Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get
Read Full Article
Benzinga
Benzinga

Coverage and analysis from United States of America. All insights are generated by our AI narrative analysis engine.

United States of America
Bias: center
You might also like

Explore More